Spago Nanomedical: Interview with CEO Mats Hansen
Research Interview
2024-03-28
07:15
Redeye invites Mats Hansen, CEO of Spago Nanomedical, for a chat after AstraZeneca’s USD 2.4bn bid on Canadian Fusion Pharma. This is a reminder that Spago’s Tumorad is also a clinical Radio Pharma candidate.
JU
Johan Unnerus
Disclosures and disclaimers